📣 #ESMO26: The late-breaking abstract lineup is taking shape! Authors & titles are online, and most of the submissions are already there. 30K+ delegates already registered from around the world, so this means new data, new insights and new opportunities to connect. Register now! 🔗 ow.ly/hRv350ZQ7ZW

In phase 3️⃣ DESTINY-Lung04, first-line trastuzumab deruxtecan achieved a 70% response rate in advanced HER2-mutant #NSCLC vs 44.5% with pembrolizumab + chemotherapy. 🗣️Presented by @JuliaRotow of @DanaFarber at #WCLC26 Explore the findings ➡️ ascopost.com/news/september-…

A positive ctDNA result does not necessarily mean MRD. In NSCLC surveillance, 59% of patients with a positive methylation-based ctDNA result subsequently became negative, mostly without radiologic recurrence. Low-level signals around the assay’s detection limit were particularly unstable. In contrast, all three patients with clearly higher ctDNA fractions had confirmed recurrence. As ctDNA increasingly enters perioperative trials and potentially treatment decisions, perhaps the clinically relevant biomarker is not simply ctDNA+/−, but its level, persistence, and trajectory. A single low-level positive result may be a poor reason to label a patient as having molecular residual disease and escalate treatment. This is a small retrospective study, but an important warning against reducing MRD to a binary variable. I raised a similar concern when discussing SERENA-6. Unfortunately, it did not attract the editor’s interest at the time and was therefore not published in a “scientific journal.” Given the sometimes difficult-to-understand discretionary nature of editorial decisions, I have increasingly chosen to share some of my scientific views independently, as I did in the post below. jtocrr.org/article/S2666-364…

Thanks @HHorinouchi! 5 years of work, a PhD and some white hair later, delighted to share our work in @JTOonline. We show multi-omic profiling enables molecular risk stratification of stage I-III EGFRm NSCLC to inform adjuvant TKI benefit. Grateful to my mentors and co-authors 🙏🏻

5y follow up from phase II study of lorlatinib in ALK+ NSCLC @JTOonline. Shorter OS noted for EML4::ALK fusion variant 3 competed to variants 1 or 2 and with TP53 co-mutation. jto.org/article/S1556-0864(2…

Great timing for our new @JCO_ASCO review on PACC mutations & EGFR exon 20 insertions in NSCLC. “Uncommon EGFR” is no longer one disease , structure matters, and increasingly guides therapy. And #WCLC26 provided a perfect example: REZILIENT3 showed zipalertinib + chemo significantly improved PFS in 1L EGFR Ex20ins NSCLC: 14.5 vs 8.5 mo | HR 0.50 From molecular structure → rational drug development → Phase III evidence. Proud to be part of this review with a fantastic group of colleagues! @caliraf @LeXiuning @fede_monaca Dr Randulfe, Pr Heymach, Dr Zhou ascopubs.org/doi/10.1200/JCO… #LCSM #EGFR #NSCLC

ESMO is pleased to announce the #ESMOAmbassadors for #ESMO26. They will share scientific highlights, expert perspectives and insights on the latest research presented at #ESMO26 across tumour types and disciplines. 🔗Discover the Ambassadors: ow.ly/Lj2t50ZOkuo

ESMO is pleased to announce the #ESMOAmbassadors for #ESMO26. They will share scientific highlights, expert perspectives and insights on the latest research presented at #ESMO26 across tumour types and disciplines. 🔗Discover the Ambassadors: ow.ly/Lj2t50ZOkuo

🔥Multi-omic profiling enables recurrence risk stratification beyond pathological stage in resected EGFR-mutant LUAD 🆙 @JTOonline ☑Genomic instability, TP53 co-mutations & transcriptomic features profiled 🎯Multi-omic model C-index 75.4% across 4 validation cohorts 🎯High vs Low Risk in Stage I: IA HR 12.53, IB HR 18.10 🎯Benefit by Adjuvant TKI: Low Risk➖ High Risk➕ 🎙 @stephanieplsaw @danieltanmd #LCSM @OncoAlert @Larvol @EGFRResisters jto.org/article/S1556-0864(2…

🔥EGFR PACC mutations & exon 20 insertions in NSCLC: a rapidly evolving therapeutic landscape 🆙 @JCO_ASCO 🎯PACC (G719X, S768I, E709X, L747X): 2nd-gen TKIs preferred 🎯Common+PACC compound mutations: 3rd-gen TKIs 🎯Ex20ins: amivantamab, sunvozertinib (WU-KONG28), zipalertinib & firmonertinib show meaningful activity 🎙Dr. Federico Monaca @caliraf @LeXiuning #LCSM @ASCO @OncoAlert @Larvol @EGFRResisters @Exon20Group ascopubs.org/doi/full/10.120…

🎙️Monday Highlights from #WCLC26! Drs. @StephenVLiu & @NarjustFlorezMD are joined by @alexdrilon and @g_mountzios to discuss: 🔹 ARROS-1: zidesamtinib in ROS1+ lung cancer 🔹 EVOKE-03: sacituzumab govitecan + pembrolizumab 🎧 bit.ly/4hrY8Or #LungCancerConsidered #LungCancer #ThoracicOncology #Oncology

The ruling emperor of thoracic oncology #WCLC26 @iaslc @StephenVLiu